This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Liraglutide and semaglutide led to histological resolution of NASH in ~40% to 60% of patients.
Why it matters
Understanding the role of GLP-1RAs in treating NASH could provide new therapeutic options for patients with limited treatment choices. This research may lead to improved management of obesity and related metabolic disorders.
How the study worked
The study involved a review of existing literature and meta-analyses on GLP-1RAs and their effects on NASH.
What this study cannot tell us
The review primarily summarizes existing studies, and the long-term effects and safety of GLP-1RAs in NASH require further investigation.
Read the original research
Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.
Alimentary pharmacology & therapeutics, 55(8), 944-959
Citation
Barritt, A Sidney; Marshman, Emma; Noureddin, Mazen. (2022). Review article: role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know.. Alimentary pharmacology & therapeutics, 55(8), 944-959. https://doi.org/10.1111/apt.16794